A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Inclusion Criteria: * Males and females ≥18 years of age for NSCLC, TNBC, and CRPC * Males and females ≥16 years of age for NMC * Diagnosis of one of the following advanced solid tumors for which standard therapy either does not exist or has proven ineffective, intolerable or inacceptable for the participant: NMC;TNBC; NSCLC; or CRPC * Have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. CRPC participants may be enrolled with objective evidence of disease as per Prostate Cancer Working Group (PCWG2) criteria * Life expectancy ≥3 months * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1 * Have an interval of ≥3 weeks (or ≥2 weeks for NMC participants) since chemotherapy (≥6 weeks for nitrosoureas or mitomycin C), immunotherapy, hormone therapy or any other anticancer therapy or surgical intervention resection, or ≥3 half-lives for monoclonal antibodies, or ≥5 half-lives for other non-cytotoxic agents (whichever is longer) * CRPC participants must maintain ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue, antagonist or orchiectomy providing serum testosterone is \<50 ng/dL (\<1.7 nmol/L) * Participants receiving bisphosphonate or denosumab therapy must be on stable doses for at least 4 weeks before start of study therapy * Females must not be pregnant (negative urine or serum human chorionic gonadotropin test within 72 hours of study start) * Females of childbearing potential a…